The CRG developed recommendations (given below) where sufficient evidence was available from the systematic review of the literature. The recommendations have been carefully worded to reflect the strength of the body of evidence. Each recommendation has been given a grade, using the following definitions, which were set by the NHMRC:
No. |
Grade |
Recommendation |
Relevant section of document |
|
R1 |
C |
It is recommended that institutions develop an MTP that includes the dose, timing and ratio of blood component therapy for use in trauma patients with, or at risk of, critical bleeding requiring massive transfusion (Grade C). 4-5 |
4.2 |
|
R2 |
B |
C |
The routine use of rFVIIa in trauma patients with critical bleeding requiring massive transfusion is not recommended because of its lack of effect on mortality (Grade B)6 and variable effect on morbidity (Grade C).6 |
4.6 |
|
MTP, massive transfusion protocol; rFVIIa, recombinant activated factor VII